Segment Information (Tables)

9 Months Ended

Mar. 31, 2012

Segment Information [Abstract]

Revenue For Each Reportable Segment

	Three Months Ended March 31,						Nine Months Ended March 31,
(in millions)	2012			2011			2012			2011
Segment revenue:
Pharmaceutical	$	24,508.0		$	23,845.3		$	73,590.9		$	69,285.8
Medical		2,414.2			2,231.4			7,210.3			6,609.6
Total segment revenue		26,922.2			26,076.7			80,801.2			75,895.4
Corporate		(4.7	)		(5.3	)		(13.7	)		(14.7	)
Total consolidated revenue	$	26,917.5		$	26,071.4		$	80,787.5		$	75,880.7

Segment Profit By Reportable Segment

	Three Months Ended March 31,						Nine Months Ended March 31,
(in millions)	2012			2011			2012			2011
Segment profit:
Pharmaceutical	$	446.4		$	411.4		$	1,204.0		$	1,021.4
Medical		89.4			107.9			252.9			294.4
Total segment profit		535.8			519.3			1,456.9			1,315.8
Corporate		(9.2	)		(72.0	)		(68.7	)		(160.7	)
Total consolidated operating earnings	$	526.6		$	447.3		$	1,388.2		$	1,155.1